Acquired somatic mutations affecting TET oncogene family number 2 (TET2), isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and additional sex combs-like 1 (ASXL1) have been recently described in BCR-ABL-negative neoplasm, myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), MDS/MPN and acute myeloid leukemias (AMLs), including transformations of MDS or MPN.
1 TET2 mutations are diverse (frameshift, nonsense and missense mutations) and do not cluster in a particular region of the protein. In contrast, mutations affecting IDH1/2 and ASXL1 are found in restricted regions. 2, 3 None of these gene alterations are disease-specific and their incidence ranges from rare to 40%. 1 Another important observation from recent related studies is that these mutations can coexist with other pathogenetically relevant mutations including JAK2V617F, sometimes before or emerging in a subclone. 4 Therefore, and especially in view of the occurrence of these mutations across varying molecular profiles, their contribution to disease initiation, clonal evolution or blastic transformation is not clear. Also, the possibility of independently emerging multiple abnormal clones rather than monoclonal myeloproliferation is raised. In chronic myeloid leukemia (CML), BCR-ABL fusion is known to be the driver mutation. However, leukemogenesis is a complex process, and genomic heterogeneity of the chronic phase (CP) of the disease has been reported. 5 This intrinsic heterogeneity at the molecular level could support a causative link with the varying response to treatment and disease progression. Furthermore, we still do not know for sure whether the BCR-ABL fusion is really the initiating lesion. In order to describe TET2, IDH1, IDH2 and ASXL1 mutation prevalence, to investigate whether these defects could represent an important event in CML initiation, and to define the relationships between acquisition of these mutations and CML transformation and/or imatinib (IM) resistance, here we report on a mutation analysis done on paired samples from CML at diagnosis (untreated), time of IM response and, when available, complete cytogenetic response (CCR) in 91 CML patients treated with IM as first lineFmost of them from the French SPIRIT trialFand presenting five profiles of IM response at the time of analysis: (1) 25 had CCR and major molecular response (MMR) at 12 months of IM; (2) 11 were in CCR but showed a Ph negative (PhÀ) clonal evolution 12-24 months after IM (median 12 months); (3) 20 were in partial cytogenetic response (4 minor and 16 major), 3 of them with additional cytogenetic abnormalities (ÀY, þ 8, þ 8) 18 months after IM and referred as primary resistant (R1); (4) 20 were in acute transformation (14 myeloid, 6 lymphoid) 4-72 months after onset of IM (median 12 months); and (5) 15 referred as secondary IM-resistant (R2) had relapse in CP (4 molecular relapse, 6 loss of CCR and 5 hematologic relapse). Sokal scores were homogeneously distributed among the five groups except for group 2, which did not have higher scores. Except for group 1, BCR-ABL residual disease evaluated by RQ-PCR remained high (median value 0.09%, according to the International Scale (IS)).
Genomic DNA was extracted from bone marrow or peripheral blood mononuclear cells at diagnosis or at time of IM response using standard procedures. The search for mutation was performed by sequencing the entire TET2 coding gene (11 exons), the IDH1 and IDH2 exon 4 and the ASXL1 exon 12. For the TET2 p.P1617fs (C4851del) mutation, ASO-PCR detection was performed on DNA obtained from the healthy donor or unique patient number (UPN) 2 at the time of myeloid transformation or at diagnosis. For the common p.G646WfsX12 (c.1934dupG), five repeated and independent sequencing analyses confirmed the somatic status of this specific variation, as it was always found in patients' samples but was not found among the 50 healthy DNA samples from donors.
As presented in Table 1 , we identified TET2 2 'stop' mutations for UPN 1 (A2079del-p.K700fs and T4893A-p.Y1631X, both also detected at diagnosis) and one 'stop' mutation for UPN 2 (C4851del-p.P1617fs). For UPN 2, the mutation was not Letters to the Editor detected at the time of diagnosis, even by mutation-specific ASO-PCR (Figure 1 ) (sensitivity of 10 À3 , data not shown). We have excluded five missense TET2 variations in this study (all located in exon 3, i.e., p.S1107L, p.T625I, p.T395A, p.L34F and p.L34V) in cases where germline DNA was not available. Overall, only 2 patients (2.2%) in acute myeloid transformation were TET2 mutated and both presented atypical profiles: UPN 1 was in partial cytogenetic response at the time of AML-M5 myeloid transformation, arising only 4 months after diagnosis, and UPN 2 (m-BCR) was in major cytogenetic response associated with a detectable level of BCR-ABL transcript rate (o1% on the international scale) 39 months after onset of IM. These data suggest that TET2 mutations were detected at the time of disease evolution in two cases presenting both Ph þ and PhÀ cell populations. Because clonal analysis could not be made for these patients, three profiles of TET2 and BCR-ABL emergence are possible. First, TET2 could precede BCR-ABL and, in this case, all Ph þ and PhÀ cells are TET2 mutated. But the lack of detectable TET2 mutation at diagnosis of UPN 2 and in CCR patients with PhÀ clonal evolution in our study makes it unlikely. The second profile could be a biclonal disease, and in this case all Ph þ cells are TET2 wild type. But detection of TET2 mutation at diagnosis for UPN 1 is not in agreement with this hypothesis. Actually, the rapid relapse 4 months after cytogenetic response for this patient could not be related to the emergence of a PhÀ TET2-mutated subclone, of which the BCR-ABL fusion was acquired de novo. Third, BCR-ABL could occur before TET2 mutation, suggesting a late diagnosis of CML for UPN 1, that is, after occurrence of TET2 mutation, which could be in agreement with his rapid transformation.
No IDH1 or IDH2 mutation was found when the 91 CML patients were screened. To date, IDH mutations have been mainly described in blast-phase MPN and have been reported to coexist with JAK2 mutation, but in the absence of TET2 or ASXL1 mutations.
6 Surprisingly, no IDH1 or IDH2 was detected in our current study, even among the 20 CML patients in acute transformation. This result strongly suggests that IDH alterations are not a major event in CML. In fact, IDH2, but no IDH1 mutations have recently been reported by Soverini et al. 7 at a very low frequency in blast crisis CML (3 out of 178 CML cases, 1.7%).
For ASXL1 mutation screening, a total of 8 patients (8.8%) presented 'stop' mutations at diagnosis (UPN 3-10, Table 1 ). Among them, three patients (UPN 3 and UPN 4 with P.G646WfsX12(c.1934dupG), and UPN 5 with p.V751RfsX24 (c.2251insC)) reached MMR without detection of ASXL1 mutation at the time of response. One primary resistant patient (UPN 6) presenting ASXL1 'stop' mutation p.G646WfsX12 had no ASXL1 mutation at the time of resistance characterized by a partial cytogenetic response (5% Ph-positive metaphases) 18 months after onset of IM, and the patient progressed to MMR 9 months later. One patient (UPN 7) had a 23-bp deletion of p.R634RfsX16 (c.1900_1922del) at diagnosis and the mutation was still detectable at acute myeloid transformation 11 months later. In two relapsing patients presenting ASXL1 mutations at diagnosis (UPN 8 with p.S895del (c.2684_2688del), UPN 9 with p.A751RfsX24 (c.2251insC)) the mutation was also detected at cytogenetic relapse (UPN 8) or hematologic relapse (UPN 9). However, no ASXL1 mutation was detected at hematologic relapse for UPN 10 presenting p.R860SfsX3 (c.2580_2581del) at diagnosis. All other sequence variations have already been described as SNPs (data not shown). Recently, Boultwood et al. 8 have reported ASXL1 mutations in 6 of 41 (14.6%) patients from both CP and blast crisis CML. In our study, ASXL1 alterations (8.8%) were not detected when patients reached molecular response, and were not necessarily found at relapse. Also, we had detected ASXL1 mutation in only 1 patient in acute transformation out of 20. Our results therefore suggest that ASXL1 alteration is frequent in CML at diagnosis, but, unlike other myeloid malignancies, this early event is probably not associated with the pathogenesis of the CML but may rather reflect the genetic instability of the cell.
In conclusion, unlike BCR-ABL-negative MPNs, TET2, IDH1/2 and ASXL1 alterations are not a major event in CML. Our results rather suggest that these events are likely passenger mutations emerging in a context of genetic instability without major impact on disease progression or relapse.
